We examined the effect of immunosuppressant cyclosporin A (CsA) on the synthesis of tetrahydrobiopterin (BH4), which is a cofactor for nitric oxide synthase (NOS), during treatment with lipopolysaccharide (LPS) in mouse brain microvascular endothelial cells. Addition of LPS to the endothelial cells increased the BH4 content and the mRNA level of GTP-cyclohydrolase I (GTPCH), the rate-limiting enzyme of BIÌ4 synthesis, and the LPSínduced increases in both the BH4 content and expression of GTPCH mRNA were further stimulated by the cotreatment with CsA. 2,4-Diamino-6-hydroxypyrimidme, an inhibitor of GTPCH, blocked the increase in BH4 content induced by CsA during the LPS treatment. Moreover. CsA stimulated the expression of inducible NOS (iNOS) mRNA during the LPS treatment. These findings suggest that CsA stimulates LPS-induced BH4 synthesis through the induction of GTPCH, and iNOS expression. CsA may increase NO production during LPS treatment in brain microvascular endothelial cells.
Introduction
Immunosuppressors including cyclosporin A (CsA) are widely used in organ transplantation to prevent graft rejection. It is important to use immunosuppressors for successful medication after transplantation. Countermeasures to infection after transplantation are also important.
Accumulated evidence has shown that lipopolysaccharide (LPS) and/or cytokines induce the production of a large amount of nitric oxide (NO) to protect against infection (1, 2) , although the over-produced NO has a common cause with fatal damage to organs (3, 4) . The synthesis of tetrahydrobiopterin (BH4), which is a cofactor for NO synthase (NOS), is also induced along with the expression of inducible NOS (iNOS) by LPS and/or cytokines (5, 6) . The increase of the BH4 level is essential for NO production from iNOS (7, 8) . As another function, BH4 also has an antioxidative activity (9, 10) , and protects various cells against NO and/or reactive oxygen species toxicities (10) (11) (12) (13) (14) . Thus, BH4 is not only a cofactor for iNOS but also a protective factor against NO and/or reactive oxygen species toxicities.
Some investigators have reported that CsA suppresses the expression of iNOS and NO production induced by LPS and/or cytokines (15, 16) . Moreover, Hattori and Nakanishi (17) showed that CsA and FK506 increase the intracellular BH4 content in LPStreated macrophages, despite of the reduction of NO production. However, the effect of CsA on the NO producing system, including BH4 synthesis, during LPS treatment in vascular endothelial cells has not yet been clarified. The purpose of this study was to examine the effect of CsA on BH4 synthesis during LPS treatment in vascular endothelial cells.
Materials and Methods
Cell culture Mouse brain microvascular endothelial cells (second passage) were purchased from Toyobo Co. (Tokyo, Japan). The cells were cultured in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal bovine serum (FBS), 100 U/ml penicillin and 100 μg/ml streptomycin. The cells were finally grown in 100-mm culture dishes to extract total RNA or in 6-well plates to measure the biopterin content, and used throughout the experiments at 8 to 12 passages after they were purchased.
Measurement of biopterin level RH4 was measured by reverse-phase high performance liquid chromatography (HPLC) with fluorometric detection of biopterin (11) . The confluent endothelial cells in 6-well plates were washed three times with physiological saline solution (PSS, pH 7.4) containing 118.5 mM NaCl, 4.74 mM KCl, 2.5 mM CaCb, 1.18 rnM MgS0 4 , 1.18 mM KH 2 P0 4 , 2.5 mM NaHCCb, 11 mM glucose and 10 mM N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid, and treated with CsA in the presence or absence of LPS (100 ng/ml) at 37°C in 2 ml of PSS. The cells were then treated with 10% trichloroacetic acid on ice for 30 rnin. The obtained supernatant was oxidized with MnO ,, and injected into HPLC.
Measurement of GTPCH mRNA levels by reverse transcriptase (RT)-PCR
The confluent endothelial cells in 100-mm culture dishes were treated with CsA in the presence of LPS m 10 ml of PSS, and then total RNA was extracted by a modified guanidium isothiocyanate method with ISOGEN Reagent (Nippon Gene Co., Ltd., Tokyo, Japan). Reverse transcription and PCR amplification from 0.2 μg of total RNA were performed using xTth DNA polymerase (RT-PCR high Plus, Toyobo Co., Tokyo, Japan). The primer pairs used for the amplifications of iNOS and GTPCH were 5'-CGCTA-CACTTCCAACGCAAC-3' and 5'-AGGAAGTAG-GTGAGGGCTTG-3', and 5'-GGATACCAGGAGAC-CATCTCA-3' and 5 ' -TAG C ATGGTGCTA GTGA CA -GT-3', respectively. The thermocycler was programmed to give an initial cycle consisting of 60°C reverse transcription for 30 min and 94°C denaturation for 2 min, followed by 28 cycles of 94°C denaturation for 1 min and 58°C annealing/extension. To control the amounts of total RNA, parallel RT-PCR of glyceraldehyde-3-phosphate-dehydrogenase (GAPDH) was performed as a reference, using the primer pair of 5'-TCCACCACCCTGTTGCTGTA-3' and 5'-ACCACAGTCCATGCCATCAC-3'. The PCR products were electrophoresed on a 3% NuSieve® 3:1 agarose (FMC Co., ME, USA) gel containing ethidium bromide and visualized using UV-induced fluorescence (5). Statistical analysis Data are presented as means ± S.E.M. of η observations. The significance of the observed differences was determined by analysis of variance followed by Bonferroni's method. Differences between means were considered significant when Ρ was less than 0.05.
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Results
Stimulation of LPS-induced BH4 synthesis by CsA.
We examined whether CsA affects the intracellular BH4 content during LPS treatment in the endothelial cells. The addition of CsA alone increased the BH4 content in a concentration-dependent manner (Fig. 1A) . LPS (100 ng/ml) also increased the BH4 content, and the LPS-induced increase in BH4 content was further stimulated by the co-treatment with CsA in a concentration-dependent manner (Fig. IB) . Moreover, the increase in the BH4 content induced by LPS plus CsA was completely blocked by the treatment with 2,4-diamino-6-hydroxypyrimidine (DAPH), an inhibitor of GTPCH (Fig. 2) .
Stimulation of LPS-induced expression of iNOS and GTPCH mRNAs by CsA.
We next examined whether CsA induces GTPCH mRNA expression during LPS treatment. The induction of GTPCH mRNA expression by LPS was stimulated by the co-treatment with CsA in a concentrationdependent manner (Fig. 3) . Moreover, CsA also enhanced the iNOS mRNA expression during the LPS treatment (Fig. 3) .
Discussion
LPS and/or cytokines are well known to induce BH4 synthesis along with the induction of iNOS in various cell types (5, 6) . The induction of BH4 synthesis is believed to be essential for NO production from iNOS during LPS treatment (7, 8) . In the present study, we
reduction in NO production. These discrepancies seem to be dependent on the types of cells used. The large amount of NO produced by iNOS contributes not only to protection against infection, but also to the pathogenesis of vascular failure (1,2, 18,  19) . The systemic inflammatory response is also associated with the production of reactive oxygen species (20, 21) . NO has been shown to react with superoxide and hydrogen peroxide, and to produce peroxynitrite, which is highly toxic (22) (23) (24) . Reactions between reactive oxygen species and NO seem to be implicated in the development of many diseases, including inflammation (25, 26) . During the past several years, we and others have shown that the increase in intracellular BH4 content has a protective role against reactive oxygen species-and NO-induced cell injury (9) (10) (11) (12) (13) (14) 27) . Recently, Mogi et al. (28) also suggested that BH4 has a self-protective role in cytokine-induced apoptotic cell death in mouse osteoblastic cells. Therefore, it is also possible that the CsA-induced increase in the BH4 level during LPS treatment may have a protective role against NO and/or reactive oxygen species toxicities.
In conclusion, our findings indicate that CsA stimulates the increase in BH4 content through a de novo pathway in LPS-treated mouse brain microvascular endothelial cells. There are at least two possibilities for LPS (100 ng/ml) observed that the addition of CsA further stimulated the BH4 synthesis and the expression of GTPCH mRNA in LPS-treated endothelial cells. DAHP, an inhibitor of GTPCH activity, inhibited the CsAinduced increase in the BH4 level. Thus, CsA seems to stimulate the BH4 synthesis during LPS treatment through the induction of GTPCH in the brain microvascular endothelial cells. Moreover, CsA also enhanced the level of iNOS mRNA during the LPS treatment. These observations suggest that CsA may stimulate LPS-induced NO production. On the other hand, there have been some reports showing that CsA suppress the expression of iNOS and NO production induced by LPS and/or cytokines in vascular smooth muscle cells (15, 16) . Hattori and Nakanishi (17) showed that CsA and FK506 increase in intracellular the BH4 level in LPS-treated macrophages, despite the the role of increased BH4 by CsA during LPS treatment. Firstly, the increased BH4 functions as a cofactor of NOS, and stimulates NO production. Secondly, the increased BH4 protects the cells against NO and/or reactive oxygen species toxicities. Future studies will be needed to determine the role of increased BH4 by CsA during LPS treatment in brain microvascular endothelial cells.
